» Articles » PMID: 15159460

Practice Parameter: Medical Treatment of Infantile Spasms: Report of the American Academy of Neurology and the Child Neurology Society

Overview
Journal Neurology
Specialty Neurology
Date 2004 May 26
PMID 15159460
Citations 113
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To determine the current best practice for treatment of infantile spasms in children.

Methods: Database searches of MEDLINE from 1966 and EMBASE from 1980 and searches of reference lists of retrieved articles were performed. Inclusion criteria were the documented presence of infantile spasms and hypsarrhythmia. Outcome measures included complete cessation of spasms, resolution of hypsarrhythmia, relapse rate, developmental outcome, and presence or absence of epilepsy or an epileptiform EEG. One hundred fifty-nine articles were selected for detailed review. Recommendations were based on a four-tiered classification scheme.

Results: Adrenocorticotropic hormone (ACTH) is probably effective for the short-term treatment of infantile spasms, but there is insufficient evidence to recommend the optimum dosage and duration of treatment. There is insufficient evidence to determine whether oral corticosteroids are effective. Vigabatrin is possibly effective for the short-term treatment of infantile spasm and is possibly also effective for children with tuberous sclerosis. Concerns about retinal toxicity suggest that serial ophthalmologic screening is required in patients on vigabatrin; however, the data are insufficient to make recommendations regarding the frequency or type of screening. There is insufficient evidence to recommend any other treatment of infantile spasms. There is insufficient evidence to conclude that successful treatment of infantile spasms improves the long-term prognosis.

Conclusions: ACTH is probably an effective agent in the short-term treatment of infantile spasms. Vigabatrin is possibly effective.

Citing Articles

Efficacy and tolerability of celastrol and edaravone in the multiple-hit rat model of infantile spasms.

Shandra O, Wang Y, Coles L, Mowrey W, Li Q, Liu W Epilepsy Behav. 2024; 162:110159.

PMID: 39577370 PMC: 11681605. DOI: 10.1016/j.yebeh.2024.110159.


Exploring Infantile Epileptic Spasm Syndrome: A Proteomic Analysis of Plasma Using the Data-Independent Acquisition Approach.

Huang H, Cao D, Hu Y, He Q, Zhao X, Chen L J Proteome Res. 2024; 23(10):4316-4326.

PMID: 38857073 PMC: 11459594. DOI: 10.1021/acs.jproteome.4c00298.


Epileptic spasms relapse is associated with response latency but not conventional attributes of post-treatment EEG.

Deckard E, Sathe R, Tabibzadeh D, Terango A, Groves A, Rajaraman R Epilepsia Open. 2024; 9(3):1034-1041.

PMID: 38588009 PMC: 11145600. DOI: 10.1002/epi4.12931.


Acthar Gel Treatment for Patients with Autoimmune and Inflammatory Diseases: An Historical Perspective and Characterization of Clinical Evidence.

Kaplan J, Askanase A, Chu D, Abdellatif A, Basu D, Mirsaeidi M Clin Drug Investig. 2023; 43(10):739-761.

PMID: 37792273 PMC: 10575998. DOI: 10.1007/s40261-023-01303-5.


West Syndrome and the Importance of Routine Physical Examinations and Parental Education: A Case Report.

Dias Freitas F, Cavaco Raposo S, Luis Nogueira A Cureus. 2022; 14(11):e31848.

PMID: 36579257 PMC: 9792333. DOI: 10.7759/cureus.31848.


References
1.
Wohlrab G, Boltshauser E, Schmitt B, Schriever S, Landau K . Visual field constriction is not limited to children treated with vigabatrin. Neuropediatrics. 1999; 30(3):130-2. DOI: 10.1055/s-2007-973477. View

2.
Yamamoto H, Asoh M, Murakami H, Kamiyama N, Ohta C . Liposteroid (dexamethasone palmitate) therapy for West syndrome: a comparative study with ACTH therapy. Pediatr Neurol. 1998; 18(5):415-9. DOI: 10.1016/s0887-8994(98)00003-4. View

3.
Gibbs E, FLEMING M, Gibbs F . Diagnosis and prognosis of hypsarhythmia and infantile spasms. Pediatrics. 1954; 13(1):66-73. View

4.
Jeavons P, Bower B . The natural history of infantile spasms. Arch Dis Child. 1961; 36:17-22. PMC: 2012697. DOI: 10.1136/adc.36.185.17. View

5.
Wohlrab G, Boltshauser E, Schmitt B . Vigabatrin as a first-line drug in West syndrome: clinical and electroencephalographic outcome. Neuropediatrics. 1998; 29(3):133-6. DOI: 10.1055/s-2007-973549. View